Abstract: The invention generally relates to solid forms of berberine ursodeoxycholate, and to pharmaceutical compositions, and methods of preparation and therapeutic use thereof. In particular, the invention relates to solid forms of berberine ursodeoxycholate and pharmaceutical compositions thereof useful in treating and/or preventing various diseases or disorders, including metabolic disorders, heart diseases, neurodegenerative diseases and liver diseases.

Abstract: The invention provides compositions and methods for treating, reducing or preventing cytokine storm, for example, in connection with a viral infection (e.g., by SARS-CoV-2), drug treatment or therapy, trauma or an inflammatory disease, or a related disease and disorder.

Abstract: The present disclosure provides a method and system for quantifying a degree of blending of virgin and aged asphalt in HRAM. The method includes the following steps: first, constructing a relational equation between the microscale modulus of recycled asphalt in a fully blended state and the content of the aged asphalt; measuring the microscale modulus of the recycled asphalt, the microscale modulus of the aged asphalt, the microscale modulus of the virgin asphalt, and the content of the aged asphalt in the HRAM in situ; inputting the dates above into the relational equation to obtain the microscale modulus of the recycled asphalt in the fully blended state; and based on the microscale modulus of the recycled asphalt measured in situ and the microscale modulus of the recycled asphalt in the fully blended state, obtaining the degree of blending of the virgin and aged asphalt in the HRAM.

Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

Abstract: A preparation method of a Lentinula edodes polysaccharide rich in ?-glucan includes: (1) extracting the Lentinula edodes polysaccharide to obtain a filtrate; (2) concentrating the filtrate to obtain a supernatant; (3) precipitating a crude Lentinula edodes polysaccharide from the supernatant using anhydrous ethanol to obtain a first precipitate; and (4) purifying the first precipitate to obtain the Lentinula edodes polysaccharide. The Lentinula edodes polysaccharide rich in the ?-glucan has stable quality, and its yield, polysaccharide content and ?-glucan content are significantly improved compared with water extraction and alcohol precipitation methods in the related art. In vitro pharmacological experiments prove that the Lentinula edodes polysaccharide rich in the ?-glucan has good anti-inflammatory activity and can be applied to preparation of drugs or health foods.

Abstract: The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: An ultra-wideband (UWB) ranging method comprises determining, by a first device, that the first device is within proximity of a second device. Responsive to the determination, the first device negotiates a value to use as a UWB session key for securing UWB communications with the second device. The negotiation occurs via a communication protocol different from a UWB communication protocol. The first device controls a UWB subsystem therein to encrypt information communicated via the UWB subsystem based on the negotiated value of the UWB session key instead of a default value for the UWB session key that is specified in the UWB communication protocol. The information facilitates determining the distance between the first device and the second device.

Abstract: The invention generally relates to solid forms of berberine ursodeoxycholate, and to pharmaceutical compositions, and methods of preparation and therapeutic use thereof. In particular, the invention relates to solid forms of berberine ursodeoxycholate and pharmaceutical compositions thereof useful in treating and/or preventing various diseases or disorders, including metabolic disorders, heart diseases, neurodegenerative diseases and liver diseases.

Abstract: The present disclosure provides compositions and methods for engineered cellular compositions and methods of immunotherapy utilizing the same. Compositions of the present disclosure for immune cell regulation comprise a chimeric antigen receptor polypeptide, a T cell receptor polypeptide, and combinations thereof.

Abstract: The present invention provides an engineered immune cell targeting BCMA and use thereof. In particular, the present invention provides a CAR specifically targeting BCMA, the CAR comprising an antigen-binding domain which is an S-derived scFv, an antibody heavy chain variable region as shown in SEQ ID NO: 9 and an antibody light chain variable region as shown in SEQ ID NO: 10. The present invention also provides a CAR-T cell comprising the CAR, a double CAR- and CAR-T cell comprising the S-derived scFv, and related use thereof. Compared to CAR-T cells constructed using other scFvs, the constructed CAR-T cell of the present invention has a better killing effect and tumor elimination capability.

Abstract: In some embodiments, the present disclosure provides an algorithm for a data-driven intelligent adaptive model of an automobile cab based on a biometric identification technology. The algorithm includes the following steps: acquiring driving posture data, the driving posture data including driver information, automobile man-computer parameter information, and seat position information; building a feature extraction model of the driving posture data and screening feature vectors playing a significant role in predicting a seat position by the feature extraction model; building a prediction model of a comfortable seat position by a back propagation (BP) neural network and inputting the screened feature vectors to perform training on the prediction model; and inputting specific feature vectors to obtain the seat position information and accordingly adjust the seat position.

Abstract: Provided are a universal chimeric antigen receptor (CAR) T cell and preparation method and application thereof. The binding of the cell HLA-A/HLA-B to the TCR is inhibited; the TCR gene expression is silenced; the invention may be used for allogeneic tumor treatment and does not cause GVHD and HVG reaction during allogeneic infusion, and thus improves the survival and antineoplastic effect of allogeneic CAR-T cells in the recipient.

Abstract: A hydraulic power system for a downhole device, including a first motor, a first hydraulic pump, a second hydraulic pump, a first main oil circuit, a second main oil circuit, a switching control module and a first execution module. The first motor has a first output shaft which drives the first hydraulic pump and has an oil outlet connected to an input end of the first main oil circuit and a second output shaft which drives the second hydraulic pump and has an oil outlet connected to an input end of the second main oil circuit; the first execution module is connected to an output end of the first main oil circuit; displacement of the first hydraulic pump is smaller than that of the second hydraulic pump; and the switching control module is connected between the first main oil circuit and the second main oil circuit.

Abstract: The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.

Abstract: The invention provides novel pharmaceutical compositions of berberine or a derivative or analog of berberine, or a salt thereof, in combination with one or more omega-3 fatty acids or esters thereof, and methods of their use in treating inflammatory bowel disease.

Abstract: Provided in the present invention are the maintenance of the programmed chronic liver injury of FAH gene-deficient animals and an application thereof in the preparation of heterologous liver models. The present invention discloses a programmed NTBC controlling (NTBCP) scheme with a fixed cycle period, the scheme enabling animal models to survive for a long time in a state of chronic liver injury, and being capable of achieving a high heterologous replacement rate after a heterologous hepatocyte transplantation is performed.

Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: A first user equipment (UE) is configured to establish a first tethered connection with a second UE 104 and a second tethered connection with at least a third UE. The first UE identifies a plurality of network slices provided by a network. The first UE selects at least a first network slice for the second UE and selects at least a second network slice for the at least third UE. The first UE wirelessly communicates data for the second UE over the at least first network slice using a first upstream link. The first UE wirelessly communicates data for the at least third UE over the at least second network slice using a second upstream link. The first upstream link and the second upstream link are concurrently maintained.

Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.